Chief Executive Officer & Co-Founder
Ashleigh Palmer, co-founder of Provention and its CEO, is a life sciences industry entrepreneur and innovator with more than 30 years’ experience and expertise in corporate strategy formulation, preclinical and clinical drug evaluation and product development and commercialization. During his career, Mr. Palmer has served as CEO for multiple biopharma companies (both private and public) and has held numerous board director and chairman positions. In addition to Provention, Mr. Palmer currently serves as a non-executive director on the board of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide for certain life-threatening and debilitating critical care and chronic cardiopulmonary conditions. Mr. Palmer is also President of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry.
From 2015 through 2017, Mr. Palmer served as Executive Chairman of Celimmune, LLC, a clinical development-stage immunotherapy company he co-founded, dedicated to developing therapies for celiac disease and intestinal lymphoma. Celimmune was acquired by Amgen Inc. in November 2017.
Prior to founding Provention, Celimmune and CBV, Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt). Under his leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world’s first selective pulmonary vasodilator, INOmax®, acquired by Mallinckrodt in 2015 for $2.3 billion.
Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing leadership at Reckitt Benckiser. Educated in the UK, Mr. Palmer received his MBA from the University of Bradford and his BSc honors in Biochemistry and Applied Molecular Biology from the University of Manchester.